Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Prostate Cancer

Free Subscription Articles published in Oncogene Retrieve available abstracts of 62 articles: HTML format

Single Articles

January 2022
1. XU L, Zhao B, Butler W, Xu H, et al
   Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer.
   Oncogene. 2022 Jan 20. pii: 10.1038/s41388-021-02155.
   PubMed     Abstract available
   
   
   
2. CANNISTRACI A, Hascoet P, Ali A, Mundra P, et al
   MiR-378a inhibits glucose metabolism by suppressing GLUT1 in prostate cancer.
   Oncogene. 2022 Jan 17. pii: 10.1038/s41388-022-02178.
   PubMed     Abstract available
   
   
   
3. HAN W, Liu M, Han D, Li M, et al
   RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition.
   Oncogene. 2022 Jan 3. pii: 10.1038/s41388-021-02135.
   PubMed     Abstract available
   
   
   December 2021
4. MIRZAKHANI K, Kallenbach J, Rasa SMM, Ribaudo F, et al
   Correction to: The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells.
   Oncogene. 2021 Dec 20. pii: 10.1038/s41388-021-02125.
   PubMed    
   
   
   November 2021
5. LEE YC, Lin SC, Yu G, Zhu M, et al
   Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition.
   Oncogene. 2021 Nov 29. pii: 10.1038/s41388-021-02131.
   PubMed     Abstract available
   
   
   
6. MAZZU YZ, Liao YR, Nandakumar S, Jehane LE, et al
   Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer.
   Oncogene. 2021 Nov 20. pii: 10.1038/s41388-021-02118.
   PubMed     Abstract available
   
   
   October 2021
7. CHERIF C, Nguyen DT, Paris C, Le TK, et al
   Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity.
   Oncogene. 2021 Oct 28. pii: 10.1038/s41388-021-02039.
   PubMed     Abstract available
   
   
   
8. MIRZAKHANI K, Kallenbach J, Rasa SMM, Ribaudo F, et al
   The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells.
   Oncogene. 2021 Oct 19. pii: 10.1038/s41388-021-02060.
   PubMed     Abstract available
   
   
   
9. HU L, Chen X, Narwade N, Lim MGL, et al
   Single-cell analysis reveals androgen receptor regulates the ER-to-Golgi trafficking pathway with CREB3L2 to drive prostate cancer progression.
   Oncogene. 2021 Oct 5. pii: 10.1038/s41388-021-02026.
   PubMed     Abstract available
   
   
   September 2021
10. LABANCA E, Bizzotto J, Sanchis P, Anselmino N, et al
    Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel.
    Oncogene. 2021 Sep 28. pii: 10.1038/s41388-021-02008.
    PubMed     Abstract available
    
    
    
11. ZHU M, Peng R, Liang X, Lan Z, et al
    P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasis.
    Oncogene. 2021 Sep 1. pii: 10.1038/s41388-021-02000.
    PubMed     Abstract available
    
    
    August 2021
12. PARK SH, Fong KW, Mong E, Martin MC, et al
    Going beyond Polycomb: EZH2 functions in prostate cancer.
    Oncogene. 2021 Aug 4. pii: 10.1038/s41388-021-01982.
    PubMed     Abstract available
    
    
    July 2021
13. LIU C, Armstrong CM, Ning S, Yang JC, et al
    ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling.
    Oncogene. 2021 Jul 16. pii: 10.1038/s41388-021-01914.
    PubMed     Abstract available
    
    
    June 2021
14. HAGIWARA M, Fushimi A, Yamashita N, Bhattacharya A, et al
    MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells.
    Oncogene. 2021 Jun 23. pii: 10.1038/s41388-021-01899.
    PubMed     Abstract available
    
    
    
15. LAUNONEN KM, Paakinaho V, Sigismondo G, Malinen M, et al
    Chromatin-directed proteomics-identified network of endogenous androgen receptor in prostate cancer cells.
    Oncogene. 2021 Jun 14. pii: 10.1038/s41388-021-01887.
    PubMed     Abstract available
    
    
    
16. PAN T, Lin SC, Lee YC, Yu G, et al
    Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone.
    Oncogene. 2021 Jun 14. pii: 10.1038/s41388-021-01874.
    PubMed     Abstract available
    
    
    
17. LIAO Y, Liu Y, Shao Z, Xia X, et al
    A new role of GRP75-USP1-SIX1 protein complex in driving prostate cancer progression and castration resistance.
    Oncogene. 2021 Jun 2. pii: 10.1038/s41388-021-01851.
    PubMed     Abstract available
    
    
    May 2021
18. LEE HC, Ou CH, Huang YC, Hou PC, et al
    Correction: YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer.
    Oncogene. 2021 May 19. pii: 10.1038/s41388-021-01836.
    PubMed    
    
    
    
19. CRONIN R, Brooke GN, Prischi F
    The role of the p90 ribosomal S6 kinase family in prostate cancer progression and therapy resistance.
    Oncogene. 2021 May 10. pii: 10.1038/s41388-021-01810.
    PubMed     Abstract available
    
    
    
20. ZHU Y, Dalrymple SL, Coleman I, Zheng SL, et al
    Correction: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
    Oncogene. 2021 May 6. pii: 10.1038/s41388-021-01805.
    PubMed    
    
    
    April 2021
21. WATSON MJ, Berger PL, Banerjee K, Frank SB, et al
    Aberrant CREB1 activation in prostate cancer disrupts normal prostate luminal cell differentiation.
    Oncogene. 2021 Apr 12. pii: 10.1038/s41388-021-01772.
    PubMed     Abstract available
    
    
    
22. PUHR M, Eigentler A, Handle F, Hackl H, et al
    Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer.
    Oncogene. 2021 Apr 1. pii: 10.1038/s41388-021-01754.
    PubMed     Abstract available
    
    
    March 2021
23. PURAYIL HT, Zhang Y, Black JB, Gharaibeh R, et al
    Nuclear betaArrestin1 regulates androgen receptor function in castration resistant prostate cancer.
    Oncogene. 2021 Mar 10. pii: 10.1038/s41388-021-01730.
    PubMed     Abstract available
    
    
    
24. ZHOU J, Wang Y, Wu D, Wang S, et al
    Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer.
    Oncogene. 2021 Mar 9. pii: 10.1038/s41388-021-01737.
    PubMed     Abstract available
    
    
    
25. RIEDEL M, Berthelsen MF, Cai H, Haldrup J, et al
    In vivo CRISPR inactivation of Fos promotes prostate cancer progression by altering the associated AP-1 subunit Jun.
    Oncogene. 2021 Mar 5. pii: 10.1038/s41388-021-01724.
    PubMed     Abstract available
    
    
    
26. LEE HC, Ou CH, Huang YC, Hou PC, et al
    YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer.
    Oncogene. 2021 Mar 4. pii: 10.1038/s41388-021-01718.
    PubMed     Abstract available
    
    
    
27. GALBRAITH LCA, Mui E, Nixon C, Hedley A, et al
    PPAR-gamma induced AKT3 expression increases levels of mitochondrial biogenesis driving prostate cancer.
    Oncogene. 2021 Mar 2. pii: 10.1038/s41388-021-01707.
    PubMed     Abstract available
    
    
    February 2021
28. ZHU Y, Dalrymple SL, Coleman I, Zheng SL, et al
    Correction to: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
    Oncogene. 2021 Feb 9. pii: 10.1038/s41388-021-01640.
    PubMed    
    
    
    
29. MA Y, Zha J, Yang X, Li Q, et al
    Long-chain fatty acyl-CoA synthetase 1 promotes prostate cancer progression by elevation of lipogenesis and fatty acid beta-oxidation.
    Oncogene. 2021 Feb 9. pii: 10.1038/s41388-021-01667.
    PubMed     Abstract available
    
    
    
30. LIN C, Blessing AM, Pulliam TL, Shi Y, et al
    Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling.
    Oncogene. 2021 Feb 2. pii: 10.1038/s41388-021-01658.
    PubMed     Abstract available
    
    
    
31. LIU PI, Chang AC, Lai JL, Lin TH, et al
    Melatonin interrupts osteoclast functioning and suppresses tumor-secreted RANKL expression: implications for bone metastases.
    Oncogene. 2021;40:1503-1515.
    PubMed     Abstract available
    
    
    January 2021
32. FORMAGGIO N, Rubin MA, Theurillat JP
    Loss and revival of androgen receptor signaling in advanced prostate cancer.
    Oncogene. 2021 Jan 8. pii: 10.1038/s41388-020-01598.
    PubMed     Abstract available
    
    
    
33. YIN L, Li J, Wang J, Pu T, et al
    MAOA promotes prostate cancer cell perineural invasion through SEMA3C/PlexinA2/NRP1-cMET signaling.
    Oncogene. 2021 Jan 8. pii: 10.1038/s41388-020-01615.
    PubMed     Abstract available
    
    
    
34. KWON OJ, Zhang L, Jia D, Xin L, et al
    Sox2 is necessary for androgen ablation-induced neuroendocrine differentiation from Pten null Sca-1(+) prostate luminal cells.
    Oncogene. 2021;40:203-214.
    PubMed     Abstract available
    
    
    December 2020
35. ROGGERO CM, Jin L, Cao S, Sonavane R, et al
    A detailed characterization of stepwise activation of the androgen receptor variant 7 in prostate cancer cells.
    Oncogene. 2020 Dec 15. pii: 10.1038/s41388-020-01585.
    PubMed     Abstract available
    
    
    
36. SHARMA S, Pei X, Xing F, Wu SY, et al
    Regucalcin promotes dormancy of prostate cancer.
    Oncogene. 2020 Dec 15. pii: 10.1038/s41388-020-01565.
    PubMed     Abstract available
    
    
    November 2020
37. HALDRUP J, Strand SH, Cieza-Borrella C, Jakobsson ME, et al
    FRMD6 has tumor suppressor functions in prostate cancer.
    Oncogene. 2020 Nov 28. pii: 10.1038/s41388-020-01548.
    PubMed     Abstract available
    
    
    
38. BUCKUP M, Rice MA, Hsu EC, Garcia-Marques F, et al
    Plectin is a regulator of prostate cancer growth and metastasis.
    Oncogene. 2020 Nov 20. pii: 10.1038/s41388-020-01557.
    PubMed     Abstract available
    
    
    
39. SINGH KB, Hahm ER, Kim SH, Wendell SG, et al
    A novel metabolic function of Myc in regulation of fatty acid synthesis in prostate cancer.
    Oncogene. 2020 Nov 16. pii: 10.1038/s41388-020-01553.
    PubMed     Abstract available
    
    
    October 2020
40. WANG YA, Sfakianos J, Tewari AK, Cordon-Cardo C, et al
    Molecular tracing of prostate cancer lethality.
    Oncogene. 2020 Oct 12. pii: 10.1038/s41388-020-01496.
    PubMed     Abstract available
    
    
    
41. BHAGIRATH D, Liston M, Patel N, Akoto T, et al
    MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.
    Oncogene. 2020 Oct 9. pii: 10.1038/s41388-020-01493.
    PubMed     Abstract available
    
    
    September 2020
42. ZHU Y, Dalrymple SL, Coleman I, Zheng SL, et al
    Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
    Oncogene. 2020 Sep 28. pii: 10.1038/s41388-020-01479.
    PubMed     Abstract available
    
    
    
43. QIAN K, Wang G, Ju L, Liu J, et al
    A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype.
    Oncogene. 2020 Sep 25. pii: 10.1038/s41388-020-01476.
    PubMed     Abstract available
    
    
    
44. LIN SR, Wen YC, Yeh HL, Jiang KC, et al
    EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer.
    Oncogene. 2020 Sep 22. pii: 10.1038/s41388-020-01468.
    PubMed     Abstract available
    
    
    
45. WEN S, He Y, Wang L, Zhang J, et al
    Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer.
    Oncogene. 2020 Sep 11. pii: 10.1038/s41388-020-01456.
    PubMed     Abstract available
    
    
    August 2020
46. SHAH K, Gagliano T, Garland L, O'Hanlon T, et al
    Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing.
    Oncogene. 2020 Aug 20. pii: 10.1038/s41388-020-01429.
    PubMed     Abstract available
    
    
    
47. WANG Z, Li Y, Wu D, Yu S, et al
    Correction: Nuclear receptor HNF4alpha performs a tumor suppressor function in prostate cancer via its induction of p21-driven cellular senescence.
    Oncogene. 2020 Aug 20. pii: 10.1038/s41388-020-1290.
    PubMed     Abstract available
    
    
    
48. SHIN SH, Kim I, Lee JE, Lee M, et al
    Loss of EGR3 is an independent risk factor for metastatic progression in prostate cancer.
    Oncogene. 2020 Aug 14. pii: 10.1038/s41388-020-01418.
    PubMed     Abstract available
    
    
    
49. KO CJ, Hsu TW, Wu SR, Lan SW, et al
    Inhibition of TMPRSS2 by HAI-2 reduces prostate cancer cell invasion and metastasis.
    Oncogene. 2020 Aug 10. pii: 10.1038/s41388-020-01413.
    PubMed     Abstract available
    
    
    July 2020
50. KOHNO S, Linn P, Nagatani N, Watanabe Y, et al
    Pharmacologically targetable vulnerability in prostate cancer carrying RB1-SUCLA2 deletion.
    Oncogene. 2020 Jul 21. pii: 10.1038/s41388-020-1381.
    PubMed     Abstract available
    
    
    
51. WHITLOCK NC, Trostel SY, Wilkinson S, Terrigino NT, et al
    MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity.
    Oncogene. 2020 Jul 17. pii: 10.1038/s41388-020-01389.
    PubMed     Abstract available
    
    
    June 2020
52. NOLLET EA, Cardo-Vila M, Ganguly SS, Tran JD, et al
    Androgen receptor-induced integrin alpha6beta1 and Bnip3 promote survival and resistance to PI3K inhibitors in castration-resistant prostate cancer.
    Oncogene. 2020 Jun 21. pii: 10.1038/s41388-020-1370.
    PubMed     Abstract available
    
    
    
53. KOHVAKKA A, Sattari M, Shcherban A, Annala M, et al
    AR and ERG drive the expression of prostate cancer specific long noncoding RNAs.
    Oncogene. 2020 Jun 17. pii: 10.1038/s41388-020-1365.
    PubMed     Abstract available
    
    
    May 2020
54. YADAV S, Anbalagan M, Baddoo M, Chellamuthu VK, et al
    Somatic mutations in the DNA repairome in prostate cancers in African Americans and Caucasians.
    Oncogene. 2020;39:4299-4311.
    PubMed     Abstract available
    
    
    April 2020
55. LI M, Nopparat J, Aguilar BJ, Chen YH, et al
    Intratumor delta-catenin heterogeneity driven by genomic rearrangement dictates growth factor dependent prostate cancer progression.
    Oncogene. 2020 Apr 20. pii: 10.1038/s41388-020-1281.
    PubMed     Abstract available
    
    
    
56. HE Y, Mi J, Olson A, Aldahl J, et al
    Androgen receptor with short polyglutamine tract preferably enhances Wnt/beta-catenin-mediated prostatic tumorigenesis.
    Oncogene. 2020;39:3276-3291.
    PubMed     Abstract available
    
    
    
57. LI J, Pu T, Yin L, Li Q, et al
    MAOA-mediated reprogramming of stromal fibroblasts promotes prostate tumorigenesis and cancer stemness.
    Oncogene. 2020;39:3305-3321.
    PubMed     Abstract available
    
    
    March 2020
58. ADLER AJ, Mittal P, Hagymasi AT, Menoret A, et al
    GRK2 enforces androgen receptor dependence in the prostate and prostate tumors.
    Oncogene. 2020;39:2424-2436.
    PubMed     Abstract available
    
    
    February 2020
59. LOVERIDGE CJ, Slater S, Campbell KJ, Nam NA, et al
    BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration.
    Oncogene. 2020;39:1797-1806.
    PubMed     Abstract available
    
    
    
60. CHEN X, Xiong X, Cui D, Yang F, et al
    DEPTOR is an in vivo tumor suppressor that inhibits prostate tumorigenesis via the inactivation of mTORC1/2 signals.
    Oncogene. 2020;39:1557-1571.
    PubMed     Abstract available
    
    
    
61. ALI S, Zhang Y, Zhou M, Li H, et al
    Functional deficiency of DNA repair gene EXO5 results in androgen-induced genomic instability and prostate tumorigenesis.
    Oncogene. 2020;39:1246-1259.
    PubMed     Abstract available
    
    
    January 2020
62. WANG M, Nagle RB, Knudsen BS, Cress AE, et al
    Centrosome loss results in an unstable genome and malignant prostate tumors.
    Oncogene. 2020;39:399-413.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: